APP and Down syndrome: Specific clinical phenotype (posterior variant, logopenic variant, frontal variant, and Down's syndrome variant of AD) PLUS in vivo evidence of AD pathology (abnormal CSF biomarker, amyloid PET, genetic evidence in PSEN1, PSEN2, or APP)